The classification of analgesics as long- or short-acting reflects differences in formulation design and drug behavior within the body. Short-acting opioids, such as immediate-release morphine, oxycodone, and hydrocodone, are typically used for acute or breakthrough pain. They require dosing every few hours due to their rapid absorption and clearance. In contrast, long-acting formulations are designed to release the active drug more slowly, providing sustained analgesia for 12 to 24 hours and offering more consistent pain management in chronic settings (1).

Formulation is the most visible distinction. Many long-acting analgesics achieve their duration through extended-release tablets, transdermal systems, or specialized coatings that slow absorption, when they would otherwise demonstrate a shorter duration of action. These modifications do not change the drug itself but rather modify how quickly it enters circulation. For example, oxycodone can be formulated for either immediate or extended release, depending on clinical need (2).

However, a drug’s duration is not defined by formulation alone. Patient-specific variables and co-administered medications can dramatically influence how long a drug remains active. Factors such as renal or hepatic impairment, age, body composition, and drug interactions can alter an analgesic’s expected behavior. For instance, in a patient with renal dysfunction, morphine’s active metabolites may accumulate, thereby extending the analgesic and sedative effects, even when the immediate-release form is used (1).

One of the most important (but often overlooked) determinants of analgesic duration are drug–drug interactions, especially through effects on the cytochrome P450 (CYP450) enzyme system. Many opioids are metabolized by CYP450 enzymes in the liver. When other medications inhibit these enzymes, they can slow the metabolism of opioids, causing them to remain active longer than intended. This can turn a standard dose into something longer-acting and potentially more dangerous. Conversely, drugs that induce CYP450 enzymes can accelerate metabolism, shortening the duration of effect and reducing analgesic efficacy.

Certain antifungals, antibiotics, and antiretrovirals may inhibit metabolism, resulting in prolonged effects, whereas anticonvulsants and some steroids may have the opposite effect. In patients taking multiple medications, these interactions can transform a short-acting analgesic into a long-acting one (or vice versa) in ways that significantly impact safety and symptom control. This is particularly relevant for older adults and individuals with chronic illnesses, for whom polypharmacy is common and whose organ function may already be compromised (3).

Furthermore, genetic differences in metabolism and opioid sensitivity mean that the same formulation may behave differently in different individuals. Some patients may process opioids rapidly, shortening the expected duration, while others may experience extended effects, even at standard doses. Although genetic testing is not routine in clinical practice, it can help explain why two patients may respond very differently to the same medication.

Although long-acting opioids offer advantages in terms of adherence and consistent pain relief, they are not without risk. Several studies have shown that patients taking long-acting opioids are at a higher risk of unintentional overdose compared to those taking short-acting opioids, even when total opioid exposure is equivalent (4). For this reason, initiating opioid therapy with short-acting formulations is often safer, especially in opioid-naive individuals.

The distinction between short- and long-acting analgesics is not absolute. While formulation plays a central role, the true duration of effect depends on metabolism, drug interactions, patient physiology, and comorbid conditions. Safe and effective opioid prescribing requires an understanding of both the medication and the clinical context, including how other drugs might affect an analgesic’s efficacy.

References

1. Noori A, Busse JW, Sadeghirad B, et al. Individual opioids, and long- versus short-acting opioids, for chronic noncancer pain: Protocol for a network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98(43):e17647. doi:10.1097/MD.0000000000017647
2. Gudin JA, Mogali S, Jones JD, Comer SD. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013;125(4):115-130. doi:10.3810/pgm.2013.07.2684
3. Preskorn SH. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes. J Psychiatr Pract. 2020;26(2):126-134. doi:10.1097/PRA.0000000000000458
4. Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med. 2015;175(4):608-615. doi:10.1001/jamainternmed.2014.8071